期刊文献+

磁共振成像在帕金森病诊断中的应用现状及研究进展 被引量:6

MRI in Diagnosis of Parkinson's Disease
下载PDF
导出
摘要 帕金森病(PD)是常见的神经退行性运动障碍性疾病之一,其神经病理学标志包括黑质和腹侧被盖区多巴胺能神经元损失,并伴随路易体形成。尽管传统磁共振成像(MRI)T1、T2加权成像可以显示黑质结构,但其对原发性PD的诊断几乎没有帮助。近年来,MRI技术的发展和新图像分析方法如结构性MRI、扩散张量成像、血氧水平依赖功能MRI以及磁共振波谱等的应用,为PD无创伤性脑形态学及功能变化研究提供了有效手段。本文就以上内容做一综述。 Parkinson's disease (PD) is one of the commonest neurodegenerative movement disorders, the neuro- pathological signs of which includes loss of dopaminergic neurons in substantia nigra (SN) and ventral tegmental area, accompa- nied by Lewy body formation. Conventional magnetic resonance imaging (MRI) T1, T2 -weighted imaging can show the struc- ture of SN, but it helps idiopathic PD less. Recently development of MRI technology and applications of new image analysis methods such as structural MRI, diffusion tensor imaging (DTI), blood oxygen -level dependent MRI (BOLD -fMRI) and magnetic resonance spectroscopy provide effective means for the research of noninvasive brain morphology and functional changes.
作者 王蕾 熊中奎
出处 《中国全科医学》 CAS CSCD 北大核心 2013年第23期2771-2773,共3页 Chinese General Practice
基金 浙江省自然科学基金(Y2100035) 浙江省公益性技术应用研究计划(2010C33116) 浙江省中医药科技计划(2011ZA108 2012ZB162) 浙江省教育厅科研项目(Y201018615) 绍兴市科技计划(2010A23021)
关键词 帕金森病 磁共振成像 诊断 综述 Parkinson disease Magnetic resonance imaging Diagnosis Review
  • 相关文献

参考文献22

  • 1Brooks DJ. Imaging approaches to Parkinson disease [J]. J Nucl Med, 2010, 51 (4): 596 - 609.
  • 2封华,刘承伟.帕金森病早期诊断的研究进展[J].医学综述,2010,16(18):2775-2777. 被引量:6
  • 3Laakso MP, Partanen K, Riekkinen P, et al. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: an MR/study [J]. Neurology, 1996, 46 (3): 678-681.
  • 4Camicioli R, Moore MM, Kinney A, et al. Parkinson's disease is associated with hipp-oeampal atrophy [ J ]- Mov Disord, 2003, 18 (7): 784-790.
  • 5Jur/que C, Ramirez - Ruiz B, Tolosa E, et al. Amygdalar and hippocampal MRI volu- metric reductions in Parkinson's disease with dementia [ J ]. Mov Disord, 2005, 20 (5) : 540 -544.
  • 6Bouchard TP, Malykhin N, Martin WR, et al. Age and dementia - associated atrophy predominates in the hippocampal head and a- mygdala in Parkinson's disease [J]. Neum- biol Aging, 2008, 29 (7): 1027-1039.
  • 7Bruck A, Kurki T, Kaasinen V, et al. Hip- pocampal and prefrontal atrophy in patients with early non -demented Parkinson's disease is related to cognitive impairment [J]. J Neu- rol Neurosurg Psychiatry, 2004, 75 (10) : 1467 - 1469.
  • 8AntoneUi F, Ray N, Strafella AP. Imaging- cognitive and behavioral symptoms in Parkin- son's disease [J]. Expert Rev Neurother, 2010, 10 (12): 1827-1838.
  • 9Ramirez - Ruiz B, Marti MJ, Tolosa E, et al. Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia [ J ]. J Neurol, 2005, 252 (11) : 1345 -1352.
  • 10Burton E J, McKeith IG, Burn D J, et al. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls [ J ]. Brain, 2004, 127 (Pt4): 791-800.

二级参考文献23

  • 1Chen JJ.Parkinson's disease:health-related quality of life,economic cost,and implications of early treatment[J].Am J Manag Care,2010,16(4):87-93.
  • 2Pahwa R,Lyons KE.Early diagnosis of Parkinson's disease:recommendations from diagnostic clinical guidelines[J].Am J Manag Care,2010,16(4):94-99.
  • 3Halperin I,Morelli M,Korczyn AD,et al.Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases[J].Neurotherapeutics,2009,6(1):128-140.
  • 4Schiess M,Oh I.Serum uric acid and clinical progression in Parkinson disease:potential biomarker for nigrostriatal failure[J].Arch Neuro1,2008,65 (6):716-723.
  • 5Bogdanov M,Matson WR,Wang L,et al.Metabolomic profiling to develop blood biomarkers for Parkinson's disease[J].Brain,2008,131 (2):389-396.
  • 6Sato S,Mizuno Y,Hattori N.Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease[J].Neurology,2005,64(6):1081-1083.
  • 7Shi M,Caudle WM,Zhang J.Biomarker discovery in neurodegenerative diseases:a proteomic approach[J].Neurobiol Dis,2009,35(2):157-164.
  • 8Zecca L,Wilms H,Geick S,et al.Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra:implications for Parkinson's disease[J].Acta Neuropathol,2008,116(1):47-55.
  • 9Mollenhauer B,Cullen V,Kahn I,et al.Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration[J].Exp Neurol,2008,213 (2):315-325.
  • 10Yasuda T,Mochizuki H.The regulatory role of a-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease[J].Apoptosis,2010.Epub ahead of print.

共引文献5

同被引文献84

引证文献6

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部